318 related articles for article (PubMed ID: 25659729)
1. Transplant for MDS: challenges and emerging strategies.
Tamari R; Castro-Malaspina H
Best Pract Res Clin Haematol; 2015 Mar; 28(1):43-54. PubMed ID: 25659729
[TBL] [Abstract][Full Text] [Related]
2. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
Oran B
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
[TBL] [Abstract][Full Text] [Related]
3. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
4. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
[TBL] [Abstract][Full Text] [Related]
5. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
6. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
7. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
[TBL] [Abstract][Full Text] [Related]
8. Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M; de Wreede LC; Halkes CJ; von dem Borne PA; Kersting S; Marijt EW; Veelken H; Putter H; Schetelig J; Falkenburg JH
Haematologica; 2016 Apr; 101(4):506-14. PubMed ID: 26802054
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
10. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
Fuerst D; Mueller C; Beelen DW; Neuchel C; Tsamadou C; Schrezenmeier H; Mytilineos J
Haematologica; 2016 Feb; 101(2):241-7. PubMed ID: 26611475
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
Phillips GL
Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
[TBL] [Abstract][Full Text] [Related]
14. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia.
Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM
Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460
[TBL] [Abstract][Full Text] [Related]
16. Rapid recovery of lymphocyte subsets is not associated with protection from relapse of myelodysplastic syndromes and acute myeloid leukaemia after haematopoietic stem cell transplantation using a reduced intensity conditioning regimen and alemtuzumab.
Matthews K; Lim Z; Pearce L; Pagliuca A; Alejandro Madrigal J; Mufti GJ; Barber LD
Br J Haematol; 2010 Jun; 149(6):879-89. PubMed ID: 20346011
[TBL] [Abstract][Full Text] [Related]
17. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for myelodysplastic syndrome.
Barrett AJ; Savani BN
Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
[TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Gao L; Gao L; Gong Y; Zhang C; Chen XH; Zhang X
Leuk Res; 2013 Nov; 37(11):1482-7. PubMed ID: 24054720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
